Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients
ClinicalTrials.gov · NCT07581145 · Registry updated: 2026-05-12
- Condition / research focus
- Foot Ulcer Due to Type 2 Diabetes Mellitus
- Sponsor
- Ole Lander Svendsen
- Countries with listed sites
- Denmark
- Registry dates and results
- Start: 2026-04-24. Completion: 2029-12 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Semaglutide, 1.34 mg/mL (drug) — also listed as: ozempic
- Placebo (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Copenhagen Wound Healing Center, Bispebjerg University Hospital
Copenhagen, Denmark
Site recruitment: Recruiting